Clear The Air News Tobacco Blog Rotating Header Image

Quit Smoking

British American Tobacco to put its first quitting aid Voke on the market

http://www.cityam.com/222888/tobacco-firm-put-quitting-aid-market

British American Tobacco’s (BAT) first anti-smoking product, Voke, will arrive in shops at the end of the year, marking a victory for BAT over its rivals such as Imperial Tobacco who have similar products in development.

BAT was granted regulatory approval in 2014 by the Medicines and Healthcare Products Regulatory Agency (MHPRA).

The product will be the first approved quitting aid made by a tobacco company.

An MHPRA spokesperson said: “The MHPRA continues to encourage and actively support companies to submit medicines licence applications for electronic cigarettes and other nicotine containing products, which can be used in stop smoking services.”

Despite Evidence, FDA Targets E-Cigarettes With Proposed Regulations

Written by Raven Clabough

http://www.thenewamerican.com/usnews/health-care/item/21435-despite-evidence-fda-targets-e-cigarettes-with-proposed-regulations

Despite evidence that electronic cigarettes are both safer for users than tobacco and also help smokers kick the habit, the U.S. Food and Drug Administration has launched a campaign against them. According to FDA Commissioner Dr. Stephen Ostroff, the FDA is looking to enact a “deeming rule” that would expand the agency’s regulation of tobacco to include e-cigarettes, which do not use tobacco. Critics contend that such an illogical decision underscores that the FDA is at the behest of lobbyists that benefit financially from tobacco and nicotine addiction.

The U.S. Food and Drug Administration issued its proposal earlier this year for new rules on e-cigarettes, including reviewing new e-cig products before they are sold and outlawing sales of the e-cig devices to minors, as well as requiring health warning labels on the products. The public comment period for the proposed rulemaking ends on August 31.

The FDA has defended its proposal by asserting that e-cigarettes have not been properly studied, leaving consumers unaware of potential health effects related to their usage. (If only the government were so concerned about the lack of long-term studies on the genetically modified organisms it has approved for American consumption.)

The FDA’s stance on e-cigarettes got a boost of support from the Centers for Disease Control, which resorted to outright lies about e-cigarettes to convince users that they are no better than actual cigarettes. In May the CDC issued a statement, which read, “If you only cut down the number of cigarettes you smoke by adding another tobacco product, like e-cigarettes, you still face serious health risks. Smokers must quit smoking completely to fully protect their health — even a few cigarettes a day are dangerous.” (Emphasis added.) As previously mentioned, e-cigarettes are non-tobacco products.

Contrary to assertions by the CDC and the FDA, however, California Polytechnic State University professor of economics Michael Marlow asserts that e-cigarettes should be left alone, as they are valuable tools in helping smokers quit smoking. “If e-cigarettes help smokers reduce consumption of more harmful tobacco or maybe even allow them to quit cigarettes, even if e-cigarettes themselves are somewhat harmful, it still would be an overall reduction of harm,” Marlow states.

In fact, evidence shows that e-cigarettes have been the most successful tool to help smokers quit smoking. “E-cigarettes have become the greatest source of ‘creative destruction’ that we’ve seen against the tobacco industry,” Marlow claims, which may be the motivation behind the decision to regulate them. “Unfortunately, maybe it’s also a source of creative destruction for those who make a living out of tobacco control,” Marlow observed.

According to the Tobacco Control Journal, the nicotine replacement therapies that have been approved by the FDA, such as nicotine gum, have no better success rates than quitting cold turkey.

Some view the FDA’s proposed regulations against e-cigarettes as an attempt to keep competitive products off the market, as the pharmaceutical companies behind those nicotine replacement therapies benefit from smokers’ inability to quit.

Dr. Gilbert Ross, medical and executive director of the American Council on Science and Health, opines, “Some of the group’s advocating for this anti-science, anti-public health charade … are influenced by undisclosed but generous financial support from the pharmaceutical industry, which is devoted to keeping effective competition to its poorly performing nicotine replacement therapy patches, gums, and drugs off the market.”

The New York Times has reported that GlaxoSmithKline, which sells Nicorette gum, and Johnson & Johnson, which manufactures nicotine patches, have helped lead a “strong opposition” against e-cigarettes. What’s more, the Food and Drug Administration’s Center for Tobacco Products, which headed the regulation of e-cigarettes, is led by former lobbyist Mitch Zeller, whose consulting clients included GlaxoSmithKline.

The Washington Examiner writes on the power of pharmaceutical lobbying in Washington:

No industry spends more on lobbying in the U.S. than the drug industry, and drugmakers’ agendas are often bigger government. Without the efforts of the drug lobby, for instance, Obamacare probably would have died in the summer of 2009. President George W. Bush’s single biggest expansion of government was creating the Medicare prescription drug benefit — at the behest of the drugmakers.

“The alarmist concerns raised by the drug companies are understandable,” Dr. Ross told the Washington Examiner, “because they’re rent seeking [a term that refers to seeking profit through public policy].”

And while the drug companies profit off the sale of their ineffective smoking remedies, is it too cynical to note that the federal government makes a substantial amount of money off smokers’ inability to quit?

In 2008, the New York Times reported that the federal government collected nearly $7 billion annually in cigarette excise taxes. In 2010, the number was as high as $15.5 billion, wrote the Daily Caller.

The NY Times article went on to explain how else the federal government profits from cigarette smoking:

But taxes are not the only government revenue from cigarettes. Settlements in the late 1990s to end state lawsuits against tobacco companies mean that the cigarette industry is paying states nearly $250 billion over 25 years. Under the agreement, those payments to states will continue flowing even beyond 25 years as long as the tobacco industry is healthy. But the payments would phase out as cigarette company profits decline and would ultimately disappear if people stop smoking.

So the government has become a financial stakeholder in smoking, some would argue, even as public health officials warn people about its deadly consequences. Smoking declines as cigarette taxes increase, but a core group of smokers hang on to the habit.

Stephanie Saul, who wrote the Times article, was compelled to ask, “Would politicians shut down an industry that supplies so much money?”

In other words, who else stands to lose from the impact that e-cigarettes can have on the tobacco industry?

Meanwhile, on the other side of the Atlantic, health officials are touting the benefits of e-cigarettes. This week, Public Health England has announced that vaping is safer than smoking and could lead to the destruction of the traditional cigarette.

The Guardian reports, “The health body concluded that, on ‘the best estimate so far’, e-cigarettes are about 95% less harmful than tobacco cigarettes and could one day be dispensed as a licensed medicine in an alternative to anti-smoking products such as patches.”

A 111-page expert independent evidence review found “no evidence so far that e-cigarettes are acting as a route into smoking for children or non-smokers,” a finding that directly contradicts a study by the University of California that found that adolescents who used the devices were more likely to smoke cigarettes.

“My reading of the evidence is that smokers who switch to vaping remove almost all the risks smoking poses to their health,” said Professor Peter Hajek of Queen Mary University, who co-authored the report with Professor Ann McNeill of King’s College London.

Maybe the FDA has not yet gotten the memo.

E-Cigarettes: A New Foundation for Evidence-based Policy and Practice

Download (PDF, 1.25MB)

New prescription smoking-cessation drug not helping smokers quit

http://www.news-medical.net/news/20150818/New-prescription-smoking-cessation-drug-not-helping-smokers-quit.aspx

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine.

The findings, published online August 17 in Tobacco Control, suggest that the primary effect of varenicline (marketed as Chantix) has been to displace the use of older tobacco addiction therapies, such as nicotine patches and the antidepressant, bupropion (Zyban).

Moreover, in this population analysis, researchers said varenicline’s enhanced effectiveness in helping smokers quit, compared with other cessation aides, appeared to be short-lived, lasting for three months, after which time varenicline users no longer had higher rates of success.

“We had hoped the new pharmacotherapy would help more people quit, but this is not what is happening,” said lead author Shu-Hong Zhu, PhD, a professor in the Department of Family Medicine and Public Health and director of Center for Research and Intervention in Tobacco Control at UC San Diego. “Instead, varenicline is replacing other options like the patch, without having any significant population-level impact on quitting success.”

According to the Centers for Disease Control, almost 20 percent of U.S. adults 18 years or older are cigarette smokers. If smoking continues at the current rate among U.S. youth, one in every 13 person younger than 18 is projected to die prematurely of a smoking-related illness. Globally, tobacco use is estimated to cause nearly 6 million deaths annually.

For the study, UC San Diego School of Medicine researchers analyzed two U.S. Census Bureau surveys of smokers age 18 and older, conducted in 2003 and 2010-11, before and after varenicline became commercially available.

The surveys probed smokers’ efforts to quit in the last 12 months; their use of nicotine replacement therapies (including the nicotine patch, gum, lozenge and inhaler) and prescription medications such as bupropion and varenicline. Varenicline helps reduce nicotine cravings by binding to nicotine receptors in the brain, stimulating the release of dopamine, a neurotransmitter that helps regulate the brain’s reward and pleasure centers.

Based on responses from more than 39,000 smokers, overall use of pharmacotherapy increased from 28.7 percent of smokers trying to quit in 2003 to 31.1 percent in 2010-11, representing a 2.4 percent increase.

This slight increase in the use of cessation aides, however, did not translate into more smokers breaking the habit. In 2003, approximately 4.5 percent of smokers reported successfully quitting for at least a year, compared with 4.7 percent in 2010-11.

“We are not saying Chantix does not help smokers quit. It does, but it won’t solve America’s tobacco epidemic unless it inspires more smokers to try to quit,” Zhu said.

TSRI Chemists Report Nicotine-Chomping Bacteria May Hold Key to Anti-Smoking Therapy

http://www.scripps.edu/news/press/2015/20150806janda.html

LA JOLLA, CA – August 6, 2015 – A new study from scientists at The Scripps Research Institute (TSRI) explores a bacterial enzyme that might be used as a drug candidate to help people quit smoking. The research shows that this enzyme can be recreated in lab settings and possesses a number of promising characteristics for drug development.

“Our research is in the early phase of drug development process, but the study tells us the enzyme has the right properties to eventually become a successful therapeutic,” said Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.

The new research, published online ahead of print on August 6 in the Journal of the American Chemical Society, offers a possible alternative to current smoking cessation aids, which are shown to fail in at least 80 to 90 percent of smokers. The idea behind an enzyme therapy would be to seek out and destroy nicotine before it reaches the brain—depriving a person of the “reward” of nicotine that can trigger relapse into smoking.

For more than 30 years, Janda and his colleagues have struggled to create such an enzyme in the lab, but they recently ran across a potential enzyme found in nature—NicA2 from the bacteria known as Pseudomonas putida. It turns out this bacterium—originally isolated from soil in a tobacco field—consumes nicotine as its sole source of carbon and nitrogen.

“The bacterium is like a little Pac-Man,” said Janda. “It goes along and eats nicotine.”

In the new study, the TSRI researchers characterized the bacterial enzyme responsible for nicotine degradation and tested its potential usefulness as a therapeutic.

The researchers first combined serum (a component of blood) from mice with a dose of nicotine equivalent to one cigarette. When they added the enzyme, the nicotine’s half-life dropped from two to three hours to just 9 to 15 minutes. Janda said a higher dose of the enzyme—with a few chemical modifications—could reduce the half-life of nicotine even further and keep it from ever reaching the brain.

Next, the researchers subjected the enzyme to a barrage of tests to determine its practicality as a drug candidate. “It was a long shot,” said Janda. “If it didn’t have the right metrics, it would be a bust.”

The results were encouraging. The enzyme stayed stable in the lab for more than three weeks at 98 degrees Fahrenheit—which Janda said was “pretty remarkable.” Importantly, the researchers detected no toxic metabolites produced when the enzyme degraded nicotine.

“The enzyme is also relatively stable in serum, which is important for a therapeutic candidate,” said Song Xue, a TSRI graduate student and first author of the new study.

Janda said the next step is to alter the enzyme’s bacterial makeup, which will help mitigate potential immune liabilities and maximize its therapeutic potential.

“Hopefully we can improve its serum stability with our future studies so that a single injection may last up to a month,” added Xue.

In addition to Janda and Xue, Joel E. Schlosburg of TSRI was an author of the study, “A new strategy for smoking cessation: Characterization of a bacterial enzyme for the degradation of nicotine.”

The research was supported by the Skaggs Institute for Chemical Biology at TSRI.

Irish study to find best way to quit smoking for good

http://www.independent.ie/irish-news/health/irish-study-to-find-best-way-to-quit-smoking-for-good-31404214.html

Allison Bray

One is a global empire with testimonials from Anjelica Houston, Anthony Hopkins and Richard Branson. These stars claim to be among the millions of smokers around the world who have kicked the habit thanks to the advice of a former 100-a-day smoker who ultimately died of lung cancer.

The other is a programme run by the HSE that uses hard-hitting media ads and an online and telephone support system to encourage smokers to quit for good.

And now, the Tobacco Free Research Institute (TFRI) at the Dublin Institute of Technology is using a controlled sample of 300 smokers as guinea pigs to test the success rates of Allen Carr’s Easyway smoking cessation programme versus the HSE’s Quit.ie initiative.

The 12-month Randomised Controlled Trial (RCT), which is free for participants and funded through the Department of Health’s Lottery Fund, is intended to show which programme – if not both – is the most likely to help smokers quit for good.

The Allen Carr method was founded by the British accountant-turned-anti-smoking crusader who devised his ‘Easyway’ method of smoking cessation after trying unsuccessfully for years to quit his 100-a-day habit.

When he finally did quit after 33 years of smoking at the age of 48, he established his now world-wide chain of clinics and self-help books promoting his concept, which kept him smoke-free until his death from lung cancer at the age 72 in 2006.

The Quit.ie programme was launched by the HSE in 2011, resulting in 600,000 “quit attempts” since then.

Along with online and telephone support – including the National Smoker’s Quit Line manned six days a week – it has run a number of hard-hitting media campaigns, including the stark message that “one in every two smokers will die of a tobacco-related disease.”

The campaigns also include a series of TV ads using the late Gerry Collins, the father-of-three from Greystones, Co Wicklow, who candidly spoke of how his addiction to cigarettes was literally killing him before he died of lung cancer due to smoking in January, 2014.

“Unusually, we have recruited publicly because we want to compare these two treatment modalities,” said TFRI founder and consultant respiratory physician Professor Luke Clancy. “The Allen Carr method is well known all over the world but the efficacy has never been established,” he told the Sunday Independent.

While the number of smokers in Ireland is at its lowest ever level, at approximately 20pc of the adult population, Prof Clancy, who was instrumental in bringing in the 2004 smoking ban, said Ireland still has a way to go if we are to achieve the health department’s goal of being virtually smoke-free, with just 5pc of the population smoking by 2025. “We worried that no matter what we do, we won’t reach this target,” he said. “So we’re looking to see can we improve things.”

Already hundreds of smokers have signed up to the free controlled trial that will take place over the next 12 months in Dublin. After completing an online survey, participants are selected based on various criteria, such as age and number of cigarettes smoked a day.

Those selected can bail out any time after being randomly selected to take part in either the Allen Carr group or Quit.ie group. They will be monitored at one, three, six and 12-month intervals after signing a consent form and being assessed by a nurse who monitors weight and carbon monoxide levels in exhaled breath.

Those who stick it out for the whole year will be rewarded with the chance to enter a draw for a trips to Paris and the Caribbean.

Sunday Independent

Low-Nicotine Cigarettes Fail to Sway Smokers

https://www.ucsf.edu/news/2015/07/131046/low-nicotine-cigarettes-fail-sway-smokers

Study Finds Effectiveness of Cessation Aid Slips After 6 Months

By Suzanne Leigh on July 22, 2015

Smokers who successfully lowered their nicotine intake when they were switched to low-nicotine cigarettes were unable to curb their smoking habits in the long term, according to a study by researchers at UCSF and San Francisco General Hospital and Trauma Center.

The study, published online July 22 in the journal Addiction found that levels of cotinine, a derivative of nicotine measured in the blood, plummeted six months after smokers’ regular cigarettes were replaced with low-nicotine ones. But levels started to rebound later into the study when smokers returned to regular cigarettes, suggesting that use of low-nicotine cigarettes alone may be ultimately ineffective in weaning smokers off tobacco.

Researchers led by Neal Benowitz, MD, recruited 135 smokers who had no imminent plans to quit, but were interested in trying low-nicotine cigarettes. Fifty-five of the smokers were told to continue smoking their regular brand, which was provided at no cost, while 80 were instructed to smoke “research cigarettes” with progressively lower levels of nicotine, also provided free of charge. The nicotine was eventually tapered to just 5 percent of that used in regular cigarettes.

Both groups were asked to smoke as desired, but the research cigarette smokers were told to avoid regular cigarettes and other tobacco products. Smoking cessation manuals were given to participants interested in quitting.

At 12 months, provision of both regular and research cigarettes was terminated and both groups’ cotinine levels continued to be monitored for a further year. At the start of the study, the research cigarette group had an average cotinine level of 250ng/ml, which dropped to 113ng/ml at six months. But an upswing was evident at the 12-month mark, which continued to rise as smokers returned to their usual brands, and approximated that of the group that had consistently smoked regular cigarettes.

A total of 68 participants completed the two-year study. Just one participant in the research cigarette group had quit smoking, versus zero in the regular cigarette group.

“We don’t know that very low nicotine cigarettes will not reduce nicotine dependence, but progressively reducing nicotine content of cigarettes in the way that we did, without other means of supporting smokers, did not produce the desired results,” said Benowitz, a professor in the UCSF departments of Medicine and of Bioengineering and Therapeutic Sciences, who conducts research at the San Francisco General Hospital and Trauma Center (SFGH) Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service.

The authors attributed the rebounding cotinine levels in the research cigarette group to noncompliance.

“Cotinine levels were higher than expected given that nicotine content of the very low nicotine cigarettes was only 5 percent of that of conventional cigarettes,” said Benowitz, the paper’s first author. “We know that at six months, 30 percent reported that they had supplemented with conventional cigarettes and this had increased to 43 percent at 12 months.

“The results might have been different if regular cigarettes were not freely available, as would be the case if all cigarettes were mandated to be low in nicotine,” he added.

Smokers who received research cigarettes had stated that they consumed an average 20 cigarettes daily at the start of the study. This fluctuated slightly during the first 12 months and plunged to a reported 13 cigarettes at the two-year mark.

Federal regulation of the nicotine content of cigarettes was proposed in 1994 by Benowitz and colleague Jack Henningfield, PhD, at Johns Hopkins Medicine, as a tool to reduce nicotine dependency. The researchers hypothesized that very low levels of nicotine would prevent new smokers from becoming hooked and facilitate quitting for long-term smokers. The Family Smoking Prevention and Tobacco Act of 2009 authorized the FDA to reduce cigarette nicotine content.

“While reduction of the nicotine content in cigarettes is being considered as a national regulatory intervention to make cigarettes less addictive, our study indicated that this reduction is not likely to be effective if alternative, higher nicotine-containing cigarettes are readily available,” Benowitz said.

“Nicotine reduction would work best in the context of public education, easy access to smoking cessation services and the availability of non-combustible sources of nicotine for those who have difficulty stopping nicotine completely.”

Approximately 18 percent of American adults smoked in 2013, according to the latest figures from the Centers for Disease Control and Prevention.

Co-authors of the study are Natalie Nardone, PhD; Katherine Dains, PhD; Delia Dempsey, MD; and Peyton Jacob, PhD, from the Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service at San Francisco General Hospital and Trauma Center. Jacob and Sharon Hall, PhD, are from the UCSF Department of Psychiatry. Susan Stewart, PhD, is from the Department of Public Health Sciences at UC Davis.

The study was supported by U.S. Public Health Service grants from the National Cancer Institute, National Institute on Drug Abuse and the FDA Center for Tobacco Products. Research cigarettes were provided by Philip Morris, which had no involvement in the design and implementation of the study. First author Benowitz is a consultant to several pharmaceutical companies that market smoking cessation medications. He has served as a paid expert witness in litigation against tobacco companies. Co-author Hall has received material support for a clinical trial from Pfizer. The other authors have no conflicts to declare.

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy, a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences, as well as a preeminent biomedical research enterprise and two top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospital San Francisco.

Quitting is so hard

Download (PDF, 412KB)

U.S. Chamber Fights Smoking Laws While Hospitals and Insurers Sit on Its Board

http://www.nytimes.com/2015/07/02/business/international/many-board-members-fight-smoking-even-as-chamber-opposes-tobacco-laws.html?ref=topics&_r=0

Anthem, one of the nation’s largest health insurers, wants its members to stop smoking.

It reimburses those who enroll in smoking-cessation programs or who buy products, like nicotine patches, intended to help people quit. It has even offered to arrange sessions with a coach who talks smokers through the process of quitting.

“Smoking is an unhealthy habit,” the insurer proclaimed in one of its publications. “It’s a smart business decision to urge your employees to quit smoking.”

But Anthem’s executive vice president, Wayne S. DeVeydt, serves on the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to block antismoking laws. These include taxes on cigarettes in the Philippines, graphic health warnings on cigarette packs in Jamaica and Nepal, a plan to prohibit the display of cigarettes by retailers in Uruguay and restrictions on smoking in public spaces in Moldova.

The chamber’s global opposition to antismoking measures, reported by The New York Times this week, poses a challenge for many of the members of the organization, particularly hospitals and health insurers. Four executives of leading health care organizations, including Mr. DeVeydt, are members of the chamber’s board. The other three executives come from the Health Care Service Corporation, an insurer based in Chicago, the Steward Health Care System of Boston and the Indiana University Health system.

“Smoking is one of the leading causes of death,” Brooke Thurston, a spokeswoman for Steward, said in a statement, adding, “If the chamber is in fact advocating for increased smoking we do not agree with them on this public health issue.”

The other three companies declined to comment.

Their silence stands in contrast to opposition to the chamber’s tobacco lobbying from a surprising source: the public relations firm Burson-Marsteller.

“It’s pretty obvious that you don’t want to be seen doing the bidding of an interest which is no longer legitimate,” said David Earnshaw, president of the Brussels office of Burson-Marsteller, a company that long worked for the tobacco industry. He tried unsuccessfully to prevent a major affiliate of the chamber, based in Brussels, from issuing a position paper targeting a European proposal on plain packaging.

In a statement Tuesday, the chamber said, “we know that smoking carries obvious health risks,” but added that “we are concerned that a number of governments have acted in ways that are inconsistent with their international obligations.”

The statement said the chamber had raised “substantive concerns” about “the destruction of intellectual property and the dangerous precedent of discrimination against a legal product possibly spreading to other sectors.” It added, “We make no apology for asking governments to keep their word.”

The chamber has not addressed why it has opposed health measures like restricting smoking in public places.

The Times reported this week that the chamber lobbies against antismoking laws in many countries, pits countries against one another on tobacco issues in trade forums, and, in Washington, defends the ability of the tobacco industry to sue under future trade deals.

The chamber, which claims more than three million members, previously encountered friction over its policies. Apple abandoned the chamber in 2009 over its rejection of climate change regulation. The construction giant Skanska left in 2013 after protesting the chamber’s resistance to green building codes.

Last year, when the branch of the American Chamber of Commerce in Brussels, known as AmCham EU, drafted its paper outlining opposition to plain packaging, the only inkling of dissent came from a footnote.

“This position paper does not represent the views of all members of AmCham EU,” it said, in an italicized note at the end.

Burson-Marsteller, which has had its share of controversial clients, was an unlikely rebel against the chamber’s position. The firm developed public relations and marketing campaigns for RJR Reynolds like “Project SPA,” the introduction of its failed Premier brand of cigarettes in the 1980s. Burson, a member of AmCham EU, also worked extensively for Philip Morris U.S.A., now part of Altria, developing campaigns that included a strategy to beat back criticism of the cigarette maker’s sponsorship of women’s tennis.

But in 2010 the firm renounced tobacco. Last year, Mr. Earnshaw raised objections with AmCham EU about aligning with tobacco interests, especially with many members in the cross hairs of European regulators and lawmakers facing concerns about privacy, the dominance of technology companies based in the United States and negotiations over a trans-Atlantic trade treaty.

“I tried to stop AmCham from shooting itself in the foot,” Mr. Earnshaw said. “It’s particularly crazy at a time when there are such big issues that American companies need to be involved in.”

“AmCham is extremely influential in public affairs,” he added. “If it starts producing position papers defending big tobacco on plain packaging, it’s going to make itself look ridiculous.”

The chamber’s E.U. branch proceeded with the position paper, arguing that plain packages unfairly harmed tobacco maker’s intellectual property and posed a broader threat to trademarks, representing “a potential precedent for other sectors and consumer goods or services.”

The chamber’s argument sounded as if it could have been written by the tobacco industry. An unpublished early version of the position paper, which was obtained by The Times, reveals that the rapporteur, or primary author, was Anne-Laure Covin, an executive of Philip Morris International, which is now separate from Philip Morris U.S.A. The company had no comment.

Philip Morris was not the only company involved. The paper came from a committee at the chamber’s European Union branch run by a Time Warner executive, Vincent Jamois, whose name and corporate affiliation are on the draft version of the paper, right above Ms. Covin’s name.

In other forums, Time Warner has expressed concern about cigarettes; in 2005 the company introduced a Tobacco Depiction Policy that sought to limit the number of times people were shown smoking in movies. The goal was “to reduce or eliminate the depiction of smoking and tobacco products/brands in their feature films, unless there is a compelling creative reason for such depictions,” the policy said.

Time Warner even undertook a detailed study of the effectiveness of the policy, finding that total depictions of smoking in its movies fell to 534 in 2013 from 1,346 in 2006.

The committee Mr. Jamois leads deals with intellectual property. The tobacco industry has attracted broader corporate support by framing opposition to plain packaging as a defense of intellectual property rights.

A spokesman for Time Warner declined to comment.

Other companies and institutions whose executives are listed on the U.S. Chamber’s board include Pfizer, which markets the smoking-cessation drug Chantix.

“Tobacco use is the leading cause of preventable death in the world,” Sharon Castillo, a spokeswoman for Pfizer, said in response to questions. But she continued, “Our membership of any group comes with the clear understanding that we may not always agree with all the positions of the organization.”

Part of the chamber’s campaign seeks to discredit antismoking efforts by claiming they lack scientific evidence of effectiveness, particularly requirements that cigarettes be sold in plain packages shorn of corporate logos, or that they be covered with graphic health warnings, or sometimes a combination of the two. A letter from the chamber to the prime minister of Jamaica in 2013 was typical, contending that graphic health warnings “are not effective in reducing smoking prevalence.”

But many studies have found that plain packaging and packages covered with diseased lungs and other disturbing images make smoking less palatable.

“Graphic warnings do work, they motivate people to quit smoking,” said Seth Noar, an author of an analysis by researchers at the University of North Carolina of 37 tobacco studies.

For health care companies, a prominent role in a group that antismoking advocates see as the tobacco industry’s biggest ally can be particularly awkward. Like Anthem, the Health Care Service Corporation encourages members to stop smoking.

One video on its website called “Da Couch Potato” features an overweight man who smokes, drinks beer and watches the Chicago Bears but wants to get back in shape. A news release highlights that “smoking one pack of cigarettes per day can add up to $1,825.00 each year and tobacco use accounts for more than $96 billion a year in medical costs.”

John Cannon, HCSC’s executive vice president and chief administrative officer, is a member of the chamber’s board.

Dr. Ralph de la Torre, a cardiac surgeon and the chairman and chief executive of the Steward health system, also is a board member. One of Steward’s hospitals advertises a smoking-cessation program by saying, “There are a million reasons to quit smoking but it only takes one.”

Daniel F. Evans Jr., chief of the Indiana University Health system, is another member of the chamber’s board. His health system offers a program called “Beat Tobacco” taught by “qualified tobacco educators” who “understand the struggles and side effects of tobacco cessation.”

Lisa Gilbert, who tracks the chamber for Public Citizen, a consumer advocacy group founded by Ralph Nader, said the health companies were conflicted.

“It’s interesting to think of a company giving money to another organization to lobby while publicly proclaiming the opposite policy position,” she said. Such companies either “have no idea what’s being lobbied on and would be appalled to learn that something is diametrically opposed to what they support,” or “there is some actual reason to invest in tobacco control publicly but work to keep laws just as they are in private.”

Call for tobacco levy to fund non-smoking advertising as those quitting through NHS drop by a third in a year

http://www.heraldscotland.com/news/home-news/call-for-tobacco-levy-to-fund-non-smoking-advertising-as-those-quitting-through-nhs-d.130615462

CAMPAIGNERS have called for a levy on tobacco industry profits to fund mass media advertising of official smoking services as the numbers trying to quit using NHS assistance in Scotland fell by almost a third in a year.

Martin Williams

Scots made 73,338 attempts to give up cigarettes using health service help last year according to provisional official figures, a fall of 31per cent from 2013.

It also reveals that there were 2,876 quit attempts made by pregnant women, a drop of 73 on 2013, although an NHS statistics report says this may be partly accounted for by incomplete submissions.

The NHS report says a “plausible explanation” for the fall in quit attempts through NHS services would be the rise in the use of e-cigarettes.

A poll carried out by the ASH Scotland anti-smoking charity in April 2014 found that 45 per cent of current smokers in Scotland had tried an e-cigarette in 2014, compared to only seven per cent in 2010.

Data from a survey done in England showed a “marked increase in use of e-cigarettes for quitting” from around eight per cent of smokers trying to give up in 2012 to 35 per cent now, overtaking Nicotine Replacement Therapy (NRT) for the first time as the most popular aid for giving up smoking. The report added that “trends in Scotland may well be similar”.

ASH Scotland, however, believed another major factor of the drop in the use of NHS smoking cessation services is a lack of promotion.

Sheila Duffy, chief executive of the anti-smoking charity, described the figures as “alarming” because they showed a “real, significant drop” in the number of people setting quit dates through stop smoking services.

“Some years ago the government decided there wasn’t the funding to do mass media TV advertising of the kind that has driven people to use these services and take advantage of their expertise and the free support that is available,” she said. “I believe the lack of mass media advertising on smoking cessation over the last few years has left these vital services largely invisible to the people who need them most.

“We need to look at that again and I am calling for a levy on tobacco company profits to support smokers to quit smoking and to fund mass media advertising of stop smoking services in Scotland.”

Health organisations say smoking costs the NHS at least £2bn a year and a further £10.8bn in wider costs to society, including social-care costs of more than £1bn.

Ms Duffy added: “Scotland’s NHS stop smoking services are expert and effective in helping smokers to quit. These services matter because tobacco is responsible for about a quarter of the recorded adult deaths in Scotland every year.”

The data shows that around seven per cent of the adult smoking population in Scotland made a quit attempt with an NHS smoking cessation service in 2014. In 2013 it was 10per cent.

The proportion of smokers using NHS smoking cessation services in individual NHS boards was highest in East Dunbartonshire (12 per cent) and East Renfrewshire (10.3 per cent) and lowest in the Western Isles (3.5 per cent) and Orkney (3.7 per cent).

Simon Clark, director of the smokers’ group Forest added a tobacco levy would not work as it would “almost certainly be passed on to consumers forcing some smokers further into poverty”.

He also pointed out that smokers wanting to give up were increasingly using e-cigarettes “which mimic the act of smoking, unlike nicotine patches and other quit smoking aids”.

He added: “You can’t force people to use NHS smoking cessation services so unless the public sector learns from the private sector and embraces products that encourage more smokers to switch from traditional cigarettes, the idea is doomed to fail.”

Giles Roca, director general of the Tobacco Manufacturers’ Association said: “Tobacco control measures such as a levy would cost the Treasury billions over the next parliament and would simply provide government funding for this group to continue lobbying the government. All this comes on top of a number of tobacco control measures that have not even been implemented, let alone evaluated.

“Aside from the unwarranted intrusion on individual freedoms, this continued drive to over-regulate the UK tobacco market will simply create greater opportunities for organised crime groups involved in smuggling on a massive scale. These proposals are an unprecedented, un-evidenced, dogmatic attack on a legal industry that would have hugely damaging consequences.”

Maureen Watt, minister for public health, said the NHS stop smoking services continue to support “significant numbers of smokers” to give up despite the rise of the e-cigarette.

“Importantly, the largest number of quit attempts have come from our most deprived areas, where smoking rates are highest. This proves that stop smoking services are effective in reaching deprived groups,” she said.